Synonyms: 6α-ethyl-3α,7α,23-trihydroxy-24-nor-5β-cholan-23-sulfate | INT767
Compound class:
Synthetic organic
Comment: INT-767 is a dual farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5) agonist that is in Intercept Pharmaceuticals' development pipeline [4]. Chemically it is a semisynthetic bile acid derivative and it was synthesised and tested as the sodium salt. Preclinical data indicate INT-767's potential in both preventing and reversing organ damage due to fibrosis.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
INT-767 attenuates liver steatosis and inflammation in rodent models of steatohepatitis [1-3] and reverses age-related kidney disease in mice [5]. INT-767 has also demonstrated preventative efficacy in mouse models of diabetes- and obesity-related nephropathy [6]. |
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
Selectivity at nuclear hormone receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|